By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

OncoMed Pharmaceuticals, Inc. 

800 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-995-8200 Fax: 650-298-8600


SEARCH JOBS


Industry
Pharmaceutical

Segment
Start Up





Company News
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The 13th Annual Biotechnology Industry Organization (BIO) Investor Forum 10/7/2014 7:53:52 AM
OncoMed Pharmaceuticals, Inc. (OMED) Announces Selection Of First Small Molecule Product Candidate Targeting The Wnt Pathway Under Collaboration With Bayer Pharma AG 9/30/2014 7:57:24 AM
OncoMed Pharmaceuticals, Inc. (OMED) Presents Encouraging Data From Clinical Trials Of Tarextumab (Anti-Notch2/3) In Pancreatic Cancer And Small Cell Lung Cancer At The ESMO 2014 Congress 9/29/2014 11:12:18 AM
OncoMed Pharmaceuticals, Inc. (OMED)'s Demcizumab Phase 1b Clinical Trials Show Encouraging Safety And Anti-Tumor Activity At ESMO 9/29/2014 8:32:16 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present New And Emerging Data From Demcizumab (Anti-DLL4, OMP-21M18) And Tarextumab (Anti-Notch2/3, OMP-59R5) Clinical Studies At The European Society For Medical Oncology 2014 Congress 9/17/2014 10:30:19 AM
Redwood City's OncoMed Pharmaceuticals, Inc. (OMED) Moves Forward On Drug Trials Halted Due To Side Effects 9/4/2014 3:04:58 PM
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The Morgan Stanley (MST) Global Healthcare Conference 9/2/2014 10:27:28 AM
OncoMed Pharmaceuticals, Inc. (OMED) Says FDA Lifts Partial Hold On Cancer Drug Trials For Vantictumab 8/28/2014 7:41:38 AM
OncoMed Pharmaceuticals, Inc. (OMED) Announces Second Quarter 2014 Financial Results 8/7/2014 9:00:29 AM
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Randomized Phase 2 "ALPINE" Clinical Trial Of Tarextumab (Anti-Notch 2/3, OMP-59R5) For Pancreatic Cancer 7/16/2014 7:27:10 AM
12345678910
//-->